Long-term survival with whole abdominopelvic irradiation in platinum- refractory persistent or recurrent ovarian cancer

Gynecologic Oncology

Volumn 65, Issue 3, 1997, Pages 453-460

  Cmelak, Anthony J ^a,b   Kapp, Daniel S ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; MELPHALAN; THIOTEPA; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; HUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; SURVIVAL TIME; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0031172736     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1997.4696     Document Type: Article

References (49)

1. 1. Ozols RF, Young RC: Chemotherapy of ovarian cancer. Semin Oncol 18:222-232, 1991
2. 2. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1-6, 1996
3. 3. Thigpen JT, Vance RB, Khansur T: Second-line chemotherapy for recurrent carcinoma of the ovary. Cancer 71:1559-1564, 1993
4. 4. Bolis G, Villa A, Guarnereo P, Ferraris C, Gavoni N, Giardina G, Melpignano M, Scarfone G, Zanaboni F, Parazzini F: Survival of women with advanced ovarian cancers and complete pathologic response and second-look laparotomy. Cancer 76:128-131, 1996
5. 5. Hoskins PJ, O'Reilly SE, Swenerton KD: The 'failure-free interval' defines the likelihood of resistance to carboplatin in patients with advanced epithelial ovarian cancer previously treated with cisplatin: relevance to therapy and new drug testing. Int J Gynecol Cancer 1:205-208, 1991
6. 6. Markman M, Hakes T, Barakat R, Curtin J, Almadrones L, Hoskins W: Follow-up of Memorial Sloan-Kettering Cancer Center patients treated on National Cancer Institute Treatment Referral Center protocol 9103: paclitaxel in refractory ovarian cancer. J Clin Oncol 14:796-799, 1996
7. 7. Schray MF, Martinez A, Howes AE, Ballon SC, Podratz KC, Sikic BI, Malkasian GD: Advanced epithelial ovarian cancer: toxicity of whole abdominal irradiation after operation, combination chemotherapy, and reoperation. Gynecol Oncol 24:68-80, 1986
8. 8. Schray MF, Martinez A, Howes AE, Podratz KC, Ballon SC, Malkasian GJ, Sikic BI: Advanced epithelial ovarian cancer: salvage whole abdominal irradiation for patients with recurrent or persistent disease after combination chemotherapy. J Clin Oncol 6:1433-1439, 1988
9. 9. Schray MF, Martinez A, Howes AE: Toxicity of open-field whole abdominal irradiation as primary postoperative treatment in gynecologic malignancy. Int J Radiat Oncol Biol Phys 16:397-403, 1989
10. 10. LaRouere J, Perez-Tamayo C, Fraass B, Tesser R, Lichter AS, Roberts J, Hopkins M: Optimal coverage of peritoneal surface in whole abdominal radiation for ovarian neoplasms. Int J Radiat Oncol Biol Phys 17:607-613, 1989
11. 11. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. Am Stat Assoc J 53:457-481, 1958
12. 12. Gehan EA: A generalized Wilcoxon test for comparing arbitrarily singly-censored samples. Biometrika 52:203-233, 1965
13. 13. Cox DR: Regression models and life tables. J R Stat Soc 36:187-220, 1972
14. 14. Boring CC, Squires TS, Tong T, Montgomery S: Cancer statistics, 1994. CA Cancer J Clin 44:7-26, 1994
15. 15. Averette HE, Janicek MF, Menck HR: The National Cancer Database report on ovarian cancer. Cancer 76:1096-1103, 1995
16. 16. Cannistra SA: Cancer of the ovary. N Engl J Med 329:1550-1559, 1993
17. 17. McGuire WP: Primary treatment of epithelial ovarian malignancies. Cancer 71:1541-1550, 1993
18. 18. Malkasian GJ, Decker DG, Webb MJ: Histology of epithelial tumors of the ovary: clinical usefulness and prognostic significance of the histologic classification and grading. Semin Oncol 2:191-201, 1975
19. 19. Makar AP, Baekelandt M, Trope CG, Kristensen GB: The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer. Gynecol Oncol 56:175-180, 1995
20. 20. Omura GA, Brady MF, Homesley HD, Yordan E, Major FJ, Buchsbaum HJ, Park RC: Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol 9:1138-1150, 1991
21. 21. Dembo AJ: Abdominopelvic radiotherapy in ovarian cancer: a 10-year experience. Cancer 55:2285-2290, 1985
22. 22. Griffiths CT, Grogan RH, Hall TC: Advanced ovarian cancer: primary treatment with surgery, radiotherapy, and chemotherapy. Cancer 29:1-7, 1972
23. 23. Voest EE, van Houwelingen JD, Neijt JP: A meta-analysis of prognostic factors in advanced ovarian cancer with median survival and overall survival (measured with the log (relative risk) as main objectives. Eur J Cancer Clin Oncol 25:711-720, 1989
24. 24. Omura G, Blessing JA, Ehrlich CE, Miller A, Yordan E, Creasman WT, Homesley HD: A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma: a Gynecologic Oncology Group study. Cancer 57:1725-1730, 1986
25. 25. Tomirotti M, Perrone S, Gie P, Canaletti R, Carpi A, Biasoli R, Lombardi F, Giovanninetti A, Mensi F, Villa S, Scanni A: Cisplatin (P) versus cyclophosphamide, Adriamycin and cisplatin (CAP) for stage III-IV epithelial ovarian carcinoma: a prospective randomized trial. Tumori 74:573-577, 1988
26. 26. Gruppo Interregionale Cooperative Oncologice Ginecologia: Long-term results of a randomized trial comparing cisplatin with cisplatin and cyclophosphamide with cisplatin, cyclophosphamide, and Adriamycin in advanced ovarian cancer, I. Gynecol Oncol 45:115-117, 1992
27. 27. Williams CJ, Stewart L, Parmar M, Guthrie D: Meta-analysis of the role of platinum compounds in advanced ovarian carcinoma: the Advanced Ovarian Cancer Trialists Group. Semin Oncol 19(Suppl 2):120-128, 1992
28. 28. Advanced Ovarian Cancer Trialists Group. Chemotherapy in advanced ovarian cancer: an overview of randomized clinical trials. Br Med J 303:884-893, 1991
29. 29. Baker TR, Piver MS, Hempling RE: Long term survival by cytoreductive surgery to less than 1 cm, induction weekly cisplatin and monthly cisplatin, doxorubicin, and cyclophosphamide therapy in advanced ovarian adenocarcinoma. Cancer 74:656-663, 1994
30. 30. Maggino T, Gadducci A, Romagnolo C, Fanucchi A, Fioretti P: Times and sites of relapses after negative second look in advanced epithelial ovarian cancer. Eur J Surg Oncol 20:146-150, 1994
31. 31. Seltzer V, Vogl S, Kaplan B: Recurrent ovarian carcinoma: retreatment utilizing combination chemotherapy including cis-diamminedichloroplatinum in patients previously responding to this agent. Gynecol Oncol 21:167-176, 1985
32. 32. Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S, Jones W, Almadrones L, Lewis JJ: Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9:389-393, 1991
33. 33. Bolis G, Scarfone G, Luchini L, Ferraris C, Zanaboni F, Presti M, Giardina G, Villa A, Parazzini F: Response to second-line weekly cisplatin chemotherapy in ovarian cancer previously treated with a cisplatin-or carboplatin-based regimen. Eur J Cancer 30A: 1764-1768, 1994
34. 34. Hagopian GS, Lurain JR: Options for managing recurrent or persistent ovarian cancer. Contemp Oncol (Special Report):5-12, 1995
35. 35. Trimble EL, Adams JD, Vena D, Hawkins MJ, Friedman MA, Fisherman JS, Christian MC, Canetta R, Onetto N, Hayn R, Arbuck SG: Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. J Clin Oncol 11:2405-2410, 1993
36. 36. Gore ME, Levy V, Rustin G, Perren T, Calvert AH, Earl H, Thompson JM: Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience. Br J Cancer 72:1016-1019, 1995
37. 37. Muggia FM, Liu PY, Alberts DS, Wallace DL, O'Tolle RV, Terada KY, Franklin EW, Herrer GW, Goldberg DA, Hannagan EV: Intraperitoneal mitoxantrone or fluxuridine: effects on time-to-failure and survival in patients with minimal residual ovarian cancer after second-look laparotomy - a randomized phase II study by the Southwest Oncology Group. Gynecol Oncol 61:395-402, 1996
38. 38. Mychalczak BR, Fuks Z: The current role of radiotherapy in the management of ovarian cancer. Hematol Oncol Clin North Am 6:895-913, 1992
39. 39. Bruzzone M, Repetto L, Chiara S, Campora E, Conta PF, Orsatti M, Vitale V, Rubagotti A, Rosso R: Chemotherapy versus radiotherapy in the management of ovarian cancer patients with pathological complete response or minimal residual disease at second look. Gynecol Oncol 38:392-395, 1990
40. 40. Lambert SE: The North Thames Ovary Group - Advanced carcinoma of the ovary: a comparative trial between carboplatin versus radiotherapy as maintenance therapy. Proc Int Gynecol Cancer Soc, 1989 [as referred to in Ref. 34]
41. 41. Lawton F, Luesley D, Blackledge G, Hiton C, Kelly K, Latief T, Mould J, Spooner D, Rallason T, Wade-Evans T, Fielding J, Chan KK: A randomized trial comparing whole abdominal radiotherapy with chemotherapy following cis-platinum cytoreduction in epithelial ovarian cancer: West Midlands Ovarian Cancer Group Trial II. Clin Oncol (R Coll Radiol) 2:4-9, 1990
42. 42. Mangioni C, Epis A, Vassena L, Scalmbrinao S, Plac;a F, Columbo N, Marsoni S: Radiotherapy (RT) versus chemotherapy (CH) as second-line treatment of minimal residual disease (MRD) in advanced epithelial ovarian cancer (EOC). Proc Int Gynecol Cancer Soc, 1989 [as referred to in Ref. 34]
43. 43. Randall ME: Curative potential of primary whole-abdomen irradiation in ovarian carcinoma. South Med J 84:1119-1122, 1991
44. 44. Thomas L, Pigneux J, Chauvergne J, Stockle E, Bussiéres E, Chemin A, Toulouse C: Evaluation of whole abdominal irradiation in ovarian carcinoma with a four orthogonal fields technique. Int J Radiat Oncol Biol Phys 30:1083-1090, 1994
45. 45. Whelan TJ, Dembo AJ, Bush RS, Sturgeon JF, Fine S, Pringle JF, Rawlings GA, Thomas GM, Simm J: Complications of whole abdominal and pelvic radiotherapy following chemotherapy for advanced ovarian cancer. Int J Radiat Oncol Biol Phys 22:853-858, 1992
46. 46. Hacker NF, Berek JS, Burnison CM, Heintz PM, Juillard GJ, Lagasse LD: Whole abdominal radiation as salvage therapy for epithelial ovarian cancer. Obstet Gynecol 65:60-66, 1985
47. 47. Arian-Schad KS, Kapp DS, Hackl A, Juettner FM, Leitner H, Porsch G, Lahousen M, Pickel H: Radiation therapy in stage III ovarian cancer following surgery and chemotherapy: prognostic factors, patterns of relapse, and toxicity - a preliminary report. Gynecol Oncol 39:47-55, 1990
48. 48. Eifel PJ, Gershenson DM, Delclos L, Wharton JT, Peters LJ: Twice-daily, split-course abdominopelvic radiation therapy after chemotherapy and positive second-look laparotomy for epithelial ovarian carcinoma. Int J Radiat Oncol Biol Phys 21:1013-1018, 1991
49. 49. Randall ME, Barrett RJ, Spirtos NM, Chalus E, Homesley HD, Lentz S, Hanna M: Chemotherapy, early surgical reassesment, and hyperfractionated abdominal radiotherapy in stage III ovarian cancer: results of a Gynecologic Oncology Group Study. Int J Radiat Oncol Biol Phys 34:139-147, 1996